PharmaMar updates AACR on development of three drugs
Spanish drugmaker PharmaMar presented preclinical research data on three of its developmental products at the 97th annual meeting of the American Association of Cancer Research, held in Washington DC.
The drugs covered were: Aplidin (plitidespsin), which is in Phase II trials as a treatment for solid and hematological malignancies; Zalypsis (PM00104), which is a novel synthetic alkaloid that has demonstrated in vitro activity against solid and non-solid tumor cell lines; and PM02734 a member of the Kahalaide F family of compounds, which is currently in Phase I trials as an antitumor agent.
The firm added that the most advanced drug of the three, Aplidin, has been designated an Orphan Drug for the treatment of acute lymphoblastic leukemia and multiple myeloma by both European and US regulatory authorities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze